Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MeiraGTx Holdings Plc (MeiraGTx) is a clinical-stage genetic medicine company that develops genetic therapies for rare diseases. The company’s pipeline products including AAV-hAQP1 for radiation-induced xerostomia, sjogren’s disease, PSMA radioligand xerostomia prophylaxis and treatment; AAV-GAD which treats parkinson's disease; AAV-UPF1 and AAV-CNTFR for amyotrophic lateral sclerosis; AAV-AIPL1 which targets congenital blindness; AAV-ABCA4 for the treatment of Stargardt’s disease; and AAV-BDNF which treats genetic obesity, among others. Its therapeutic areas include salivary gland, neurodegenerative disease, ophthalmology, riboswitch regulated therapies, and genetic obesity. The company operates in the US, the UK and Ireland. MeiraGTx is headquartered in New York, the US.
Headquarters
United States of America
Address
655 Third Avenue, Suite 1115, New York City, 10016
Website
meiragtx.com
No of Employees
403
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MGTX (NASD)
Revenue (2024)
$81.4M
144.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
22.7%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
68.4%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| AAV-hAQP1 : |
| Radiation-Induced Xerostomia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company signed an agreement with Johnson & Johnson to acquire botaretigene sparoparvovec (bota-vec), an investigational therapy for X-linked retinitis pigmentosa (XLRP). |
| 2025 | Contracts/Agreements | In March, the company announced a broad strategic collaboration with Hologen Limited, a world-leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. |
| 2020 | Acquisitions/Mergers/Takeovers | In April, the company acquired Emrys Bio Inc., a biopharmaceutical company. |
Competitor Comparison
| Key Parameters | MeiraGTx Holdings Plc | Biogen Inc | 4D Molecular Therapeutics Inc | Voyager Therapeutics Inc | Brain Neurotherapy Bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York City | Cambridge | Emeryville | Lexington | Columbus |
| State/Province | New York | Massachusetts | California | Massachusetts | Ohio |
| No. of Employees | 403 | 7,500 | 196 | 141 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Keith R. Harris, Ph.D. | Chairman | Executive Board | 2015 | 73 |
| Alexandria Forbes, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2015 | 61 |
| Richard Giroux | Chief Operating Officer; Chief Financial Officer | Senior Management | 2019 | 53 |
| Robert K. Zeldin, M.D. | Chief Medical Officer | Senior Management | 2020 | 61 |
| Robert J. Wollin | Secretary; General Counsel | Senior Management | 2020 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer